Merck Takes Watson Labs To Court To Protect Fosamax

Law360, New York (September 27, 2005, 12:00 AM EDT) -- Merck & Co. is back in court fighting to protect its patent rights to Fosamax, its popular and wildly profitable osteoporosis drug. The drug maker has filed a lawsuit against Watson Laboratories, accusing the drug company of infringing on the eight patents it holds for Fosamax.

Merck filed the suit after Watson filed an Abbreviated New Drug Application with the Food and Drug Administration for 5 mg, 10mg, 35 mg, 40 mg and 70 mg alendronate sodium tablets, all of which are patented and sold by...
To view the full article, register now.